---
title: "Abeona Therapeutics (ABEO) Highlights ZEVASKYN® Launch Amid Market Uncertainty"
canonical_url: https://www.stockexpertai.com/journal/2026-03-09/abeona-therapeutics-abeo-highlights-zevaskyn-launch-amid-market-uncertainty-3
last_updated: 2026-03-09T12:14:40.987Z
section: "Stock of the Day"
author: "Sam Rivera"
publisher: Stock Expert AI
tickers: ABEO, ODFL, QXO, CSL, AAPL, MSFT, GOOGL
content_type: journal-article
---

# Abeona Therapeutics (ABEO) Highlights ZEVASKYN Launch Amid Market Uncertainty

## The Take
- Abeona's ZEVASKYN® launch offers potential growth amidst market volatility, but monitor uptake and broader economic conditions.

_Abeona Therapeutics gains attention as it announces progress in the commercial launch of its gene therapy, ZEVASKYN®, even as broader markets face headwinds._

Abeona Therapeutics (ABEO) deserves a closer look today. The company announced an update highlighting building momentum in the commercial launch of ZEVASKYN (prademagene zamikeracel), its FDA-approved, first-of-its-kind autologous gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This announcement comes at a time when the broader market is experiencing volatility, making ABEO's progress particularly noteworthy.

ZEVASKYN represents a significant advancement in the treatment of RDEB, offering a novel approach to wound management for both adult and pediatric patients. The company's update suggests positive initial uptake of the therapy, which could translate to increased revenue and market share in the long term. While ABEO shares saw a slight dip of -0.41% to $4.85 today, the news surrounding ZEVASKYN's launch is a crucial indicator of the company's potential.

Meanwhile, broader market anxieties persist. An environment of Iran-driven oil shocks and stagflation risks is creating buying opportunities in cyclical value stocks. While transportation stocks such as ODFL (-7.93%) and QXO (-4.64%), along with basic materials firm CSL (-5.40%), have experienced sharp pullbacks, some analysts remain bullish on these sectors. The SPY is also down (-1.31%) and QQQ is down (-1.50%).

Key Metrics:
* ABEO: $4.85 (-0.41%)
* ODFL: $193.97 (-7.93%)
* QXO: $21.80 (-4.64%)
* CSL: $354.56 (-5.40%)

## Related Tickers
- [ABEO](https://www.stockexpertai.com/stock/abeo)
- [ODFL](https://www.stockexpertai.com/stock/odfl)
- [QXO](https://www.stockexpertai.com/stock/qxo)
- [CSL](https://www.stockexpertai.com/stock/csl)
- [AAPL](https://www.stockexpertai.com/stock/aapl)
- [MSFT](https://www.stockexpertai.com/stock/msft)
- [GOOGL](https://www.stockexpertai.com/stock/googl)

## Frequently Asked Questions

### What is ZEVASKYN and what does it treat?
ZEVASKYN is Abeona Therapeutics' FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. It offers a novel approach to wound management for both adult and pediatric patients, representing a significant advancement in treatment.

### How is the broader market impacting ABEO?
The article highlights that while ABEO is making progress with ZEVASKYN, the broader market is experiencing volatility. This context is important for investors to understand the potential impact of market trends on ABEO's stock performance and overall investment strategy.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._